Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue

 
• By Sue Sutter
  
Landscape painting
FDA figuratively paints a therapeutic landscape when it considers whether to withdraw an accelerated approval drug with an overdue confirmatory trial. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers